Directional mast cell degranulation of tumor necrosis factor into blood vessels primes neutrophil extravasation.
Animals
Blood Circulation
Blood Vessels
/ immunology
Cell Degranulation
Cells, Cultured
Dermatitis, Contact
/ immunology
Immune System Diseases
Inflammation
/ immunology
Leukocyte Disorders
Mast Cells
/ immunology
Mice
Mice, Inbred C57BL
Mice, Knockout
Neutrophil Activation
Neutrophils
/ immunology
Receptors, Tumor Necrosis Factor, Type I
/ metabolism
Secretory Vesicles
/ metabolism
Skin
/ pathology
Tumor Necrosis Factor-alpha
/ genetics
blood vessel
contact hypersensitivity
degranulation
extravasation
inflammation
mast cell
neutrophil
tumor necrosis factor
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
09 03 2021
09 03 2021
Historique:
received:
26
06
2020
revised:
10
11
2020
accepted:
23
12
2020
pubmed:
24
1
2021
medline:
14
9
2021
entrez:
23
1
2021
Statut:
ppublish
Résumé
Tissue resident mast cells (MCs) rapidly initiate neutrophil infiltration upon inflammatory insult, yet the molecular mechanism is still unknown. Here, we demonstrated that MC-derived tumor necrosis factor (TNF) was crucial for neutrophil extravasation to sites of contact hypersensitivity-induced skin inflammation by promoting intraluminal crawling. MC-derived TNF directly primed circulating neutrophils via TNF receptor-1 (TNFR1) while being dispensable for endothelial cell activation. The MC-derived TNF was infused into the bloodstream by directional degranulation of perivascular MCs that were part of the vascular unit with access to the vessel lumen. Consistently, intravenous administration of MC granules boosted neutrophil extravasation. Pronounced and rapid intravascular MC degranulation was also observed upon IgE crosslinking or LPs challenge indicating a universal MC potential. Consequently, the directional MC degranulation of pro-inflammatory mediators into the bloodstream may represent an important target for therapeutic approaches aimed at dampening cytokine storm syndromes or shock symptoms, or intentionally pushing immune defense.
Identifiants
pubmed: 33484643
pii: S1074-7613(20)30545-8
doi: 10.1016/j.immuni.2020.12.017
pii:
doi:
Substances chimiques
Receptors, Tumor Necrosis Factor, Type I
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
468-483.e5Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.